PARP1 Human shRNA Lentiviral Particle (Locus ID 142)
CAT#: TL315488V
PARP1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
Need custom lentivirus service?
Get a free quote
CNY 11,400.00
Cited in 2 publications. |
CNY 2,950.00
CNY 1,999.00
CNY 2,700.00
Specifications
Product Data | |
Product Name | PARP1 Human shRNA Lentiviral Particle (Locus ID 142) |
Locus ID | 142 |
Synonyms | ADPRT; ADPRT 1; ADPRT1; ARTD1; pADPRT-1; PARP; PARP-1; PPOL |
Vector | pGFP-C-shLenti |
Format | Lentiviral particles |
RefSeq | NM_001618, NM_001618.1, NM_001618.2, NM_001618.3, BC037545, BC037545.1, BC008660, BC014206, BC018620, BC021045 |
Summary | This gene encodes a chromatin-associated enzyme, poly(ADP-ribosyl)transferase, which modifies various nuclear proteins by poly(ADP-ribosyl)ation. The modification is dependent on DNA and is involved in the regulation of various important cellular processes such as differentiation, proliferation, and tumor transformation and also in the regulation of the molecular events involved in the recovery of cell from DNA damage. In addition, this enzyme may be the site of mutation in Fanconi anemia, and may participate in the pathophysiology of type I diabetes. [provided by RefSeq, Jul 2008] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (2)
The use of this RNAi has been cited in the following citations: |
---|
Transcriptional Regulation of CCL2 by PARP1 Is a Driver for Invasiveness in Breast Cancer
,Dutta, P;Paico, K;Gomez, G;Wu, Y;Vadgama, JV;,
Cancers (Basel) 2020
,PubMed ID 32455851
[PARP1]
|
Notch/HES1-mediated PARP1 activation: a cell type-specific mechanism for tumor suppression
,null,
Blood
,PubMed ID 21224467
[PARP1]
|
Documents
Product Manuals |
FAQs |
SDS |